BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Circulogene, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer.

Dr. Weiss will oversee and advance the laboratory’s research efforts and further educate oncologists about CIRCULOGENE’s next-generation sequencing (NGS) technology. The proprietary NGS technology enables complete genomic load DNA, RNA and microsatellite instability (MSI) analysis with the fastest turnaround times and lowest costs in the industry, all from a single tube of blood – the only company in the industry to do so. He will also work to build a team of highly qualified medical advisors comprised of industry veterans, key opinion leaders, and distinguished scientists and researchers.

“CIRCULOGENE’s pioneering work in liquid biopsy testing and expanded molecular testing capabilities show tremendous promise for the further advancement of targeted oncology and the field of precision medicine,” said Dr. Weiss. “I look forward to our collaborative efforts to improve cancer treatment options, therapy monitoring, and patient outcomes while delivering the most accurate data for the physicians that serve them.”

“Dr. Weiss’ outstanding academic, business and oncology research background strengthens our team as we expand our laboratory’s testing capabilities and test availability in the U.S. and internationally,” said CIRCULOGENE CEO Mike Mullen.

Dr. Weiss earned his medical degree from Sackler School of Medicine in Tel Aviv, Israel. He then completed an internal medicine residency at SUNY-Downstate in Brooklyn, New York. He completed a hematology/medical oncology fellowship at the University of Colorado Health Sciences Center in Aurora, Colo., serving as Chief Fellow in his final year. He subsequently earned a master’s in Business Administration from the W.P. Carey School of Business at Arizona State University.

Board certified in internal medicine and medical oncology, Dr. Weiss has completed numerous clinical trials with investigational agents, many of which have gone on to receive FDA approval for a variety of cancers. He has received research funding from the American Cancer Society, National Foundation for Cancer Research, and the International Association for the Study of Lung Cancer.

Dr. Weiss has published more than 275 peer reviewed articles and abstracts in journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research and Cancer Cell.

CIRCULOGENE is Clinical Laboratory Improvement Amendments (CLIA) certified and provides biomarker testing for a broad range of cancers, matching results to specific drugs and clinical trials. For more information, visit our website, connect with us on LinkedIn, Facebook and Twitter, or email us at info@circulogene.com or call 855-614-7083. Clinicians interested in ordering tests may visit the Contact page on CIRCULOGENE’s website.

About CIRCULOGENE

Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed the next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood and in less than seven days, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. For more information, visit www.circulogene.com or call 855-614-7083.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128006266/en/